We estimate that the CEO of IONIS PHARMACEUTICALS INC ($IONS), Brett P. Monia, received a compensation of $13,350,777 in 2025. This is a decrease of -15.35% from an estimated $15,400,343 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on April 23, 2026. Note that parsing errors may occur.
You can track $IONS on Quiver Quantitative's $IONS stock dashboard.
$IONS Stock Insider Trading Activity
$IONS Stock insiders have traded $IONS stock on the open market 90 times in the past 6 months. Of those trades, 0 have been purchases and 90 have been sales.
Here’s a breakdown of recent trading of $IONS stock by insiders over the last 6 months:
- ELIZABETH L HOUGEN (EVP, Finance & CFO) has made 0 purchases and 5 sales selling 245,130 shares for an estimated $17,867,370.
- C FRANK BENNETT (EVP, Chief Scientific Officer) has made 0 purchases and 8 sales selling 185,040 shares for an estimated $14,960,646.
- BRETT P MONIA (Chief Executive Officer) has made 0 purchases and 3 sales selling 136,434 shares for an estimated $11,028,423.
- RICHARD S GEARY (EVP, Chief Development Officer) has made 0 purchases and 9 sales selling 125,568 shares for an estimated $9,451,247.
- SHANNON L. DEVERS (EVP, Chief Human Resources Ofc) has made 0 purchases and 12 sales selling 99,605 shares for an estimated $8,130,966.
- ERIC SWAYZE (EVP Research) has made 0 purchases and 7 sales selling 55,217 shares for an estimated $4,396,067.
- ALLENE M. DIAZ has made 0 purchases and 3 sales selling 54,878 shares for an estimated $4,354,428.
- JOSEPH III KLEIN has made 0 purchases and 8 sales selling 55,653 shares for an estimated $4,342,483.
- JOSEPH H WENDER has made 0 purchases and 6 sales selling 56,000 shares for an estimated $4,335,425.
- JOAN E HERMAN has made 0 purchases and 2 sales selling 44,000 shares for an estimated $3,173,830.
- JOSEPH BAROLDI (EVP, Chief Business Officer) has made 0 purchases and 9 sales selling 25,630 shares for an estimated $1,999,579.
- BRIAN BIRCHLER (EVP, Corp and Development Ops) has made 0 purchases and 4 sales selling 23,632 shares for an estimated $1,832,375.
- EUGENE SCHNEIDER (EVP, Chf Clinical Develop Ofcr) has made 0 purchases and 3 sales selling 21,293 shares for an estimated $1,631,254.
- JOSEPH LOSCALZO has made 0 purchases and 3 sales selling 17,032 shares for an estimated $1,284,501.
- PATRICK R. O'NEIL (EVP CLO & General Counsel) has made 0 purchases and 2 sales selling 15,370 shares for an estimated $1,213,198.
- B LYNNE PARSHALL has made 0 purchases and 3 sales selling 10,000 shares for an estimated $794,955.
- KYLE JENNE (EVP, Chf GL Pdt Str Ofcr) has made 0 purchases and 2 sales selling 6,725 shares for an estimated $506,963.
- HOLLY B. KORDASIEWICZ (EVP, Chief Development Officer) sold 4,141 shares for an estimated $313,308
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IONS Stock Hedge Fund Activity
We have seen 253 institutional investors add shares of $IONS Stock stock to their portfolio, and 194 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 7,367,066 shares (-56.0%) from their portfolio in Q4 2025, for an estimated $582,808,591
- CAPITAL WORLD INVESTORS added 5,238,571 shares (+41.2%) to their portfolio in Q4 2025, for an estimated $414,423,351
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,228,097 shares (-69.9%) from their portfolio in Q4 2025, for an estimated $255,374,753
- DEEP TRACK CAPITAL, LP removed 2,108,144 shares (-55.4%) from their portfolio in Q4 2025, for an estimated $166,775,271
- JPMORGAN CHASE & CO added 1,760,324 shares (+323.3%) to their portfolio in Q4 2025, for an estimated $139,259,231
- BELLEVUE GROUP AG removed 1,442,252 shares (-23.1%) from their portfolio in Q4 2025, for an estimated $114,096,555
- FRANKLIN RESOURCES INC added 1,314,752 shares (+19941.6%) to their portfolio in Q4 2025, for an estimated $104,010,030
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IONS Stock Analyst Ratings
Wall Street analysts have issued reports on $IONS in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
- Piper Sandler issued a "Overweight" rating on 11/04/2025
- Needham issued a "Buy" rating on 10/30/2025
- Barclays issued a "Overweight" rating on 10/30/2025
- RBC Capital issued a "Outperform" rating on 10/30/2025
- Raymond James issued a "Strong Buy" rating on 10/30/2025
- Morgan Stanley issued a "Overweight" rating on 10/30/2025
To track analyst ratings and price targets for $IONS Stock, check out Quiver Quantitative's $IONS forecast page.
$IONS Stock Price Targets
Multiple analysts have issued price targets for $IONS recently. We have seen 14 analysts offer price targets for $IONS in the last 6 months, with a median target of $104.5.
Here are some recent targets:
- Yaron Werber from TD Cowen set a target price of $108.0 on 04/23/2026
- Gary Nachman from Canaccord Genuity set a target price of $110.0 on 04/21/2026
- Michael Ulz from Morgan Stanley set a target price of $130.0 on 04/21/2026
- Jason Gerberry from B of A Securities set a target price of $111.0 on 04/09/2026
- Eliana Merle from Barclays set a target price of $106.0 on 03/26/2026
- Joseph Stringer from Needham set a target price of $105.0 on 03/25/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $120.0 on 03/25/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
